167 related articles for article (PubMed ID: 20943782)
1. Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD.
Wetmore JB; Santos PW; Mahnken JD; Krebill R; Menard R; Gutta H; Quarles LD
J Clin Endocrinol Metab; 2011 Jan; 96(1):E57-64. PubMed ID: 20943782
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Calcitriol and the parathyroid hormone-ionized calcium curve: a comparison of methodologic approaches.
Ouseph R; Leiser JD; Moe SM
J Am Soc Nephrol; 1996 Mar; 7(3):497-505. PubMed ID: 8704117
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.
Koizumi M; Komaba H; Nakanishi S; Fujimori A; Fukagawa M
Nephrol Dial Transplant; 2012 Feb; 27(2):784-90. PubMed ID: 21730210
[TBL] [Abstract][Full Text] [Related]
5. Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
Huang CY; Zheng CM; Wu CC; Lo L; Lu KC; Chu P
Nephron Clin Pract; 2012; 122(3-4):93-101. PubMed ID: 23635416
[TBL] [Abstract][Full Text] [Related]
6. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
7. Impact of parathyroidectomy on serum FGF23 and soluble Klotho in hemodialysis patients with severe secondary hyperparathyroidism.
Takahashi H; Komaba H; Takahashi Y; Sawada K; Tatsumi R; Kanai G; Suzuki H; Kakuta T; Fukagawa M
J Clin Endocrinol Metab; 2014 Apr; 99(4):E652-8. PubMed ID: 24476081
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor 23 in patients undergoing peritoneal dialysis.
Isakova T; Xie H; Barchi-Chung A; Vargas G; Sowden N; Houston J; Wahl P; Lundquist A; Epstein M; Smith K; Contreras G; Ortega L; Lenz O; Briones P; Egbert P; Ikizler TA; Jueppner H; Wolf M
Clin J Am Soc Nephrol; 2011 Nov; 6(11):2688-95. PubMed ID: 21903990
[TBL] [Abstract][Full Text] [Related]
9. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?
Oliveira RB; Cancela AL; Graciolli FG; Dos Reis LM; Draibe SA; Cuppari L; Carvalho AB; Jorgetti V; Canziani ME; Moysés RM
Clin J Am Soc Nephrol; 2010 Feb; 5(2):286-91. PubMed ID: 19965540
[TBL] [Abstract][Full Text] [Related]
10. Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects.
Martin KJ; Bell G; Pickthorn K; Huang S; Vick A; Hodsman P; Peacock M
Nephrol Dial Transplant; 2014 Feb; 29(2):385-92. PubMed ID: 24235081
[TBL] [Abstract][Full Text] [Related]
11. Postprandial Mineral Handling in Patients on Maintenance Hemodialysis.
Reinhard M; Frystyk J; Randers E; Bibby BM; Ivarsen P
J Ren Nutr; 2018 May; 28(3):175-182. PubMed ID: 29429792
[TBL] [Abstract][Full Text] [Related]
12. Acute effects of repetitive hemodialysis on circulating immunoreactive parathyroid hormone levels in uremic patients undergoing vitamin D (calcitriol) therapy.
Bellazzi R; Romanini D; Bacchella L; Nai M; Aprile C; Santagostino M; De Vincenzi A
Nephron; 1991; 57(3):273-82. PubMed ID: 2017266
[TBL] [Abstract][Full Text] [Related]
13. [Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease].
Nagano N; Miyata S; Abe M; Wakita S; Kobayashi N; Wada M
Clin Calcium; 2005 Sep; 15 Suppl 1():35-9; discussion 39-40. PubMed ID: 16272627
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
Isakova T; Wahl P; Vargas GS; Gutiérrez OM; Scialla J; Xie H; Appleby D; Nessel L; Bellovich K; Chen J; Hamm L; Gadegbeku C; Horwitz E; Townsend RR; Anderson CA; Lash JP; Hsu CY; Leonard MB; Wolf M
Kidney Int; 2011 Jun; 79(12):1370-8. PubMed ID: 21389978
[TBL] [Abstract][Full Text] [Related]
15. Lack of FGF23 response to acute changes in serum calcium and PTH in humans.
Wesseling-Perry K; Wang H; Elashoff R; Gales B; Jüppner H; Salusky IB
J Clin Endocrinol Metab; 2014 Oct; 99(10):E1951-6. PubMed ID: 25062462
[TBL] [Abstract][Full Text] [Related]
16. Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
Lu KC; Yeung LK; Lin SH; Lin YF; Chu P
Am J Kidney Dis; 2003 Dec; 42(6):1221-7. PubMed ID: 14655194
[TBL] [Abstract][Full Text] [Related]
17. The effect of an oral sodium phosphate load on parathyroid hormone and fibroblast growth factor 23 secretion in normo- and hypercalciuric stone-forming patients.
Irzyniec T; Boryń M; Kasztalska J; Nowak-Kapusta Z; Maciejewska-Paszek I; Grochowska-Niedworok E
Clin Nutr; 2020 Dec; 39(12):3804-3812. PubMed ID: 32386861
[TBL] [Abstract][Full Text] [Related]
18. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895
[TBL] [Abstract][Full Text] [Related]
19. The sigmoidal parathyroid hormone-ionized calcium curve and the set point of calcium in hemodialysis and continuous ambulatory peritoneal dialysis.
Malberti F; Corradi B; Pagliari B; Romanini D; Gazo A; Sidoti A; Baretta A; Bellazzi R; Imbasciati E
Perit Dial Int; 1993; 13 Suppl 2():S476-9. PubMed ID: 8399645
[TBL] [Abstract][Full Text] [Related]
20. Calcium-mediated parathyroid hormone suppression to assess progression of secondary hyperparathyroidism during treatment among incident dialysis patients.
Rodriguez M; Ureña-Torres P; Pétavy F; Cooper K; Farouk M; Goodman WG
J Clin Endocrinol Metab; 2013 Feb; 98(2):618-25. PubMed ID: 23365129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
